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CD44 is an adhesion molecule that varies in size due to glycosylation and insertion of
so-called variant exon products. The CD44 standard isoform (CD44s) is highly expressed
in many cells and most abundantly in cells of the hematopoietic system, whereas expres-
sion of CD44 variant isoforms (CD44v) is more restricted. CD44s and CD44v are known as
stem cell markers, first described for hematopoietic stem cells and later on confirmed for
cancer- and leukemia-initiating cells. Importantly, both abundantly expressed CD44s as
well as CD44v actively contribute to the maintenance of stem cell features, like generating
and embedding in a niche, homing into the niche, maintenance of quiescence, and relative
apoptosis resistance. This is surprising, as CD44 is not a master stem cell gene. I here
will discuss that the functional contribution of CD44 relies on its particular communication
skills with neighboringmolecules, adjacent cells and, last not least, the surroundingmatrix.
In fact, it is the interaction of the hyaluronan receptor CD44 with its prime ligand, which
strongly assists stem cells to fulfill their special and demanding tasks. Recent fundamental
progress in support of this “old” hypothesis, which may soon pave the way for most
promising new therapeutics, is presented for both hematopoietic stem cell and leukemia-
initiating cell. The contribution of CD44 to the generation of a stem cell niche, to homing of
stem cells in their niche, to stem cell quiescence and apoptosis resistance will be in focus.
Keywords: CD44, hematopoietic stem cells, leukemia-initiating cells, bone marrow niche, homing, adhesion,
dormancy, apoptosis resistance
Introduction
CD44, first described as a lymphocyte homing receptor (1), is expressed by a wide range of
hematopoietic and non-hematopoietic cells (2). Interest in CD44 increased considerably, when it
was noted that the insertion of alternatively spliced exon products in the CD44 standard or CD44
hematopoietic isoform (CD44s) strikingly affects the molecules function, such that expression of
CD44 variant isoforms (CD44v) induces ametastatic phenotype in locally growing tumor cells (2, 3).
Abbreviations: ASC, adult stem cells; bFGF, basic fibroblast growth factor; BM, bone marrow; BMP, bone morphogenetic
protein; BM-Str, BM stroma cells; C, complement; CD44s, CD44 standard isoform; CD44v, CD44 variant isoforms; CIC,
cancer initiating cells; ECM, extracellular matrix; ERM, ezrin, radixin, moesin; ESC, embryonic SC; FN, fibronectin; GAG,
glucosaminoglycan; GEM, glycolipid enriched membrane microdomains; HA, hyaluronic acid; HAS, hyaluronan synthase;
HGF, hepatocyte growth factor; HSC, hematopoietic SC; ICD, intracellular domain; kd, knockdown; ko, knockout; LIC,
leukemia initiating cells; MSC, mesenchymal SC; Mϕ, macrophages; OPN, osteopontin; PCCD4, programmed cell death
4; PDGFR, platelet-derived growth factor receptor; RTK, receptor tyrosine kinase; TGF, transforming growth factor; TPO,
thrombopoietin; VEGF, vascular endothelial growth factor; wt, wild type.
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At the time, it was surprising that a leukocyte marker is engaged
in solid tumor metastasis formation. As the hematopoietic system
is the only organ that components repeatedly shift between ses-
sile and mobile states, we argued that metastasizing tumor cells
may transiently take over part of the program of hematopoietic
cells and that this programmatic shift, which is independent
of oncogene transformation, depends to a considerable degree
on CD44 and its activities (4). This hypothesis received strong
support by the recovery of cancer- and leukemia-initiating cells
(CIC/LIC), which are defined by their capacity to take over part
of the program of stem cells (SC). In fact, CD44s/CD44v are
CIC/LIC markers (5, 6) and, most importantly, CD44 was the
first marker defined as a CIC/LIC biomarker. This implies that
CD44 is engaged in fulfilling special SC-related tasks in CIC/LIC
(7). These particular tasks include, besides growth upon serial
transplantation in xenogeneic models, self-renewal and recapit-
ulation of the heterogeneous phenotype of the parental tumor,
reflecting the differentiation capacity of CIC/LIC. It also includes,
at least for a subset of CIC/LIC, the capacity of SC to transiently
shift from a sessile toward a mobile state, which is required for
metastasis formation (7–9). Furthermore, like SC, CIC/LIC are
highly apoptosis resistant (6, 7) and may profit from the crosstalk
with the surrounding (5, 6). Notably, too, CIC/LIC are hetero-
geneous (10) and genetically instable (11). This is in line with
their disputed, not mutually exclusive origin from adult stem cells
(ASC), from oncogene-transformed committed progenitors or
from cell fusion particularly withmacrophages (Mϕ) (12). Despite
their heterogeneous origin, CIC/LIC share many features with
hematopoietic SC (HSC), like relative quiescence, longevity, drug
resistance, and support by the surrounding that for SC is called
the niche. Finally, there is strong evidence that CD44/CD44v
is engaged in many of the activities, which CIC/LIC share
with ASC (13).
CD44 is a quite abundant expressed molecule. Thus, the ques-
tion arises, what qualifies CD44 for this multitude of very special
tasks. This review outlines that two features of CD44 mostly
account for the molecule’s contribution to SC maintenance: first
and most important, CD44 crosstalks with the surrounding/the
niche. Second, CD44 is located in membrane subdomains, which
are particularly prone for collecting signal transductionmolecules,
proteases, and cytoskeletal components, and foster concerted
activities. HSC and LIC were chosen as prominent examples.
Based on the largely overlapping activities of CD44 in CIC and
LIC, some references to CIC are included, as far as deeper insight
was gained with the latter.
CD44 Structure and Ligands
CD44 are glycoproteins encoded by a single gene (14). CD44
molecules vary in size due to N- and O-glycosylation (15, 16) and
insertion of alternatively spliced exon products in the extracellular
domains of the molecule (17). The smallest, hematopoietic iso-
form (CD44s) is present on themembrane of most vertebrate cells
(3). CD44 has seven extracellular domains, a transmembrane, and
a cytoplasmic domain (18). The latter is encoded by exons 9 or 10
(19). Between domains 5 and 6 up to 10, variant exon products
can be inserted by alternative splicing (15).
CD44 is a member of the family of cartilage link proteins (15,
16). TheN-terminal region forms a globular structure. Conserved
cysteins are important for the stability of the extracellular domain,
and two cysteins in the flanking region account for correct link
domain folding (19). This globular structure contains binding sites
(AA 32–132) for collagen, laminin, fibronectin (FN), and cell sur-
face receptors like E-selectin and -selectin (20–22). Importantly,
CD44 also is the major receptor for hyaluronan (HA) (23). HA
binds to a basicmotif (AA 150–158) within the globular structure,
but outside of the link domain (23, 24). Though the HA binding
motif is present in all CD44 isoforms, not all CD44+ cells bind
HA.However, HA-binding can be induced byCD44 cross-linking,
which indicates that HA-binding depends on conformational
changes or a redistribution of CD44 in the cell membrane (25).
CD44 also has two binding sites for other glycosaminoglycans
(GAG) (26). The N-terminal globular domain is followed by a
stretch of 46 AA, which comprises exon products 5–7. This stretch
of 46 AA forms a stalk like structure (27). It is heavily glycosylated
and contains putative proteolytic cleavage sites (28). Variable exon
products are inserted in the stalk like region (29). The transmem-
brane region supports CD44 oligomerisation and contributes to
incorporation in glycolipid-enriched membrane microdomains
(GEM) (30). The cytoplasmic tail of CD44 contains binding sites
for the cytoskeletal proteins ankyrin and ezrin, radixin, moesin
(ERM). Ankyrin mediates contact with spectrin and is involved
in HA-dependent adhesion and motility (31). ERM proteins are
engaged in regulating migration, cell shape, and protein resorting
in the plasma membrane (32). The N-terminus of activated ERM
proteins binds to a motif between the transmembrane region and
the ankyrin binding site, and their C-terminus binds to F-actin.
Thereby, ERM proteins link CD44 to the actin cytoskeleton (33).
Merlin, an additional ERM family member, which lacks the actin-
binding domain, might be involved in stabilizing the junctional-
cortical actin interface through its N-terminal domain (34). The
binding of CD44 to cytoskeletal linker proteins influences signal-
ing pathways downstream of CD44, which expands the range of
CD44-mediated functions.
Finally, CD44 O-glycosylation, the transmembrane region, and
the cytoplasmic tail affect the membrane subdomain localization.
Depending on the activation state, CD44 is recruited into GEM
(35), which has great bearing on the interaction of CD44 with
extracellular ligands and the association with other transmem-
brane and cytoplasmic molecules (36, 37). These associations are
most crucial for the accessory functions of CD44 inmigration and
signal transduction. This is a sequel of the inner membrane side
organization of GEM, which favors harboring adapter and signal
transducingmolecules like src familymembers (38). Someof these
cytoplasmic adapter and signaling molecules are constitutively
associated with GEM-located CD44 (39). GEM are also prone for
internalization (40).
Unlike CD44s, CD44v is only expressed on subpopulations of
epithelial and hematopoietic cells, particularly during embryonic
development, hematopoietic cell maturation and activation, and
in some carcinoma and leukemia with a tendency toward over-
expression in CIC/LIC (41, 42). Several of the CD44v exon prod-
ucts can contain specific post-translational modifications. These
include a heparan-sulfate site in exon v3, which serves for the
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binding of heparin-binding proteins like basic fibroblast growth
factor (bFGF) (43); CD44v6 contains a binding site for hepatocyte
growth factor (HGF), vascular endothelial growth factor (VEGF),
and osteopontin (OPN) (44–46). OPN also binds to CD44v10
(47). Via these cytokine/chemokine binding sites, CD44v takes
over a central and coordinating role in receptor tyrosine kinase
(RTK) activation (48).
Briefly, CD44 is the major HA receptor. It has a multitude
of additional ligands and associates with transmembrane and
cytoplasmic molecules. This is due to several glycosylation sites,
variant exon product sequences, the insertion into GEM, and the
cytoplasmic tail structure. Noteworthy, HA binding contributes
to the GEM recruitment of CD44. Beyond forcing CD44 associa-
tions, this has bearing on CD44 internalization.
HSC/LIC CD44 and Stem Cell Genes
CD44 is a marker of ASC, including HSC and of a large range
of CIC and LIC (7, 49). In addition, there is some evidence for
pronounced CD44v expression in SC (50). Thus, the question
arose, whether CD44 is engaged in stem cell gene expression
and/or whether CD44/CD44v expression is regulated by stem cell
genes.
Embryonic SC (ESC) are characterized by expression of a set of
master SC transcription factors, Oct4, Sox2, and Nanog (51), as
well as distinct chromatin organization and epigenetic signatures,
which govern the intrinsic ability to self renew and to differen-
tiate into multiple lineages (52). Polycomb genes, which have a
role in transcriptional repression through histone modification,
associate with the promoter and regulatory regions of target genes
in ESC. Expression of master gene transcription factors and epi-
genetic regulation are maintained in HSC and LIC (53, 54), which
share with ESC Oct4, Nanog, and Myc overexpression (55, 56),
and Notch, Wnt, and Hedgehog signaling pathways, important
in shaping tissue structure, cell fate, and identity (57). In fact,
leukemia recurrence was prevented by deletion of the polycomb
gene Bmi1, important for HSC self-renewal (58).
As discussed below in concern of HSC quiescence, there are
links between CD44, Nanog, and Myc expression, and CD44 is
a target of the Wnt and Notch pathways in HSC and LIC (59–61).
However, there is no evidence that CD44 plays a central role in
regulating master gene transcription factors in HSC/LIC (62–64).
Besides master SC transcription factors, miRNA were recog-
nized as key regulators of self-renewal and SC fate (65). This
includes hematopoiesis, HSC being lost upon abrogation of Dicer,
which was ascribed to miR-125a (66). Additional miRNA overex-
pressed in HSC either promote HSC engraftment (miR-125b-5p,
miR-126-3p, miR-155) or are disadvantageous (miR-196b, miR-
181c, miR-542-5p, let7e) (67). Notably, miRNA profiles differ
significantly between HSC and lineage committed progenitors,
and miRNA profiles in hematological malignancies differ from
those ofHSC and progenitor cells. In addition,miRNAprofiles are
selective for distinct leukemia [review in Ref. (68–72)]. Nonethe-
less, there are some common trends: miR-15a, miR-29b, miR-34a,
miR-151, and miR-204 frequently act as tumor suppressors, and
miR-155, miR-96, miR-24, miR-21, miR-32, miR-106-25, and let-
7 as oncomir (73). However, the engagement of HA/CD44 on
miRNA regulation in HSC and LIC remains to be elaborated in
detail. So far, there are only sporadic hints toward amutual impact.
HA-crosslinked CD44v3 binds Nanog, Oct4, and Sox2, which
promotes miR-302 expression (74) a key player in control-
ling SC self-renewal and pluripotency (75). Also, binding of
HER2 to CD44 leads to upregulation of MTA-1 (metastasis-
associated-1), which induces silencing of the miR-139 promoter,
accompanied by increased CXCR4 expression (76). HA-CD44v6
binding promotes PKCε activation, and this increases Nanog
phosphorylation and nuclear translocation, where Nanog asso-
ciates with Drosha and an RNA helicase p68, which leads to
oncogenicmiRNA-21 transcription and a reduction in the expres-
sion of the tumor suppressor programmed cell death 4 (PCD4)
(77). CD44v6-associated overexpression of miR-21 (78) induces
pre-B-cell lymphoma (79), and is frequently observed in CML
(80). Analyzing the impact of CD44v6 on the miRNA profile
in metastasizing CIC (81) revealed CD44v6-dependent down-
regulation of the tumor suppressors let-7b, let-7d, let-7e, miR-
101, and miR-34a. The latter, which suppresses tumor growth by
CD44 downregulation (82), is abundantly expressed in CD44v6
knockdown (CD44v6kd) cells, which argues for CD44v6 to be
engaged in miR-34a silencing. On the other hand, metastasis-
promoting miR-494 and miR-21 and apoptosis-regulating miR-
24-1 (83–85) are abundant only in CD44v6-competent cells.
miRNA transcription and/or posttranscriptional regulation also
were affected by CD44v6-associated MET (86), which supports
miR-103 transcription (87). MiR-103 expression was only high in
CD44v6-competent cells.
We are also far away from a comprehensive view on the regula-
tion of CD44 via miRNA. MiR-199a binding to the CD44 30-UTR
suppresses tumorigenicity, multidrug resistance, and migration
(88, 89). The CD44 30-UTR binds additional miRNA that target
extracellular matrix (ECM) mRNA, like miR-328, miR-491, miR-
671, andmiR-512-3p. In fact, transfection-induced CD44 30-UTR
overexpression is accompanied by collagen I and FN upregulation
(90). However, stressing the need for further studies, opposing
findings have also been reported, such as downregulation of CD44
by pro-metastatic miR-373/520c (91).
Finally, aberrant and alternative splicing is frequently observed
in CIC/LIC, and CD44 ranks first in the affected genes (92).
However, no mutations were found in cis acting CD44 splice
elements (93). Thus, a genetic basis for CD44 alternative splicing
in malignancies remains questionable.
Taken together, though links between CD44 and master SC
genes, dominating SC signaling pathways, and epigenetic regula-
tion of SC genes were described, HSC do not essentially depend
on CD44. This could have been expected, as HSC are not or not
seriously affected in panCD44ko (94), CD44v10ko (95), CD44v7ko,
or CD44v6/v7ko (96–98) mice.
On the other hand, it is already known since 1990 that
CD44 is required for the development and maintenance of early
hematopoietic progenitors. In long-term bone marrow (BM) cul-
tures, tightly packed clusters of small cells, so called cobble stone
areas, develop below a stroma layer. These cobble stones contain
cells with the capacity for long-term reconstitution.When cultures
contain anti-CD44, HSC clusters do not develop (99). Further-
more, CD44 is a reliable LIC marker in many malignancies (100),
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and the first LIC biomarker that blockade severely affected LIC
maintenance, e.g., anti-CD44 drives LIC into apoptosis (101, 102).
Thus, the essential contribution of CD44 relies on the communi-
cation of SC/HSC and LIC with the surrounding. In the following
sections, those features of HSC are discussed that depend on or
are modulated by the surrounding. This includes the require-
ment for a niche to maintain quiescence and to receive signals
that drive out of quiescence toward differentiation. The latter
frequently is associated with changes in motility. Finally, HSC are
relatively apoptosis resistant. It also will be discussed, where LIC,
which resemble HSC in many respects, become less dependent
on the surrounding or respond differently due to the oncogenic
transformation.
The Endosteal Niche
The fate of a cell in the developing organism is determined by its
position (103, 104). SC reside in specialized locations, the niches,
whichminutely regulate their activity (105). Niches are composed
of epithelial and mesenchymal cells and extracellular substrates.
They govern location, adhesiveness, retention, homing, mobiliza-
tion, quiescence and activation, symmetric and asymmetric divi-
sion, and differentiation (106). Accordingly, a nichemight prevent
tumorigenesis, whichwould argue against CIC/LIC profiting from
a niche. However, there is ample evidence that a preformed niche
supports CIC/LIC survival and homing (105) and regulates the
balance between quiescence and growth (107). Beyond this, a
niche can support reprogramming of non-CIC toward CIC by
exposing them to an embryonic microenvironment (108). CD44
plays a central role in the crosstalk between SC/malignant SC and
the niche, which includes an active contribution of CD44 in niche
assembly.
The Composition of HSC and LIC Niches
A niche for HCS, where they receive instructions particularly in
respect to their lifelong capacity for self-renewal, was first pro-
posed by Schofield in 1978 (109). Only 25 years later, it was uncov-
ered that osteoblasts lining the surface of the bone play a major
role (110). Additional cellular components of the endosteal niche
are mesenchymal stem cells (MSC), osteoclasts, Mϕ, fibroblasts,
and adipocytes (111, 112). Interestingly, MSC, too, are influenced
by their surrounding. Thus, it was expected that MSC from differ-
ent tissue fulfill equivalent biological activities. On the contrary,
when implanting MSC from BM, white adipose tissue, umbili-
cal cord or skin, only BM-derived MSC spontaneously formed
a BM cavity, which was progressively replaced by hematopoi-
etic tissue and bone and permitted homing and maintenance of
long-term murine and human HSC (113). Matrix components of
the endosteal niche are HA, FN, laminin, and collagen that are
secreted by endosteal niche cells and support HSC adhesion, qui-
escence, and self-renewal. Prominent cytokines and chemokines
secreted by BM stroma cells (BM-Str) and/or captured by the BM
stroma are thrombopoetin (TPO), SDF1, OPN, and parathyroid
hormone. TPO promotes HSC quiescence (114). SDF1 supports
quiescence and affects apoptosis resistance (115). OPN is engaged
in lodgment to the endosteum (116), and parathyroid hormone
supports trabecular network formation of osteoblasts and HSC
expansion (117).
Hematopoietic SC avail on a second niche, the vascular niche,
which is located in proximity to endothelial cells (118). Though
components and activities of the endosteal and the vascular
niche are partly overlapping (119), distinct to the endosteal
niche, the vascular niche plays a major role in HSC homing and
hematopoietic progenitor egress. The vascular niche also supports
hematopoietic progenitor expansion and maturation. In line with
these special duties, reticular cells in the vascular niche express
IL6, HGF, OPN, and SDF1 at high or higher levels than cells in
the osteogenic niche (120).
Thus, possibly distinct to ASC in solid organs, HSC dispose of
two niches. The requirement for two niches might be linked to the
general feature of cells of the hematopoietic system that are not
sessile and circulate through the body to fulfill upon request their
tasks in loco, and thereafter patrol again through the organism.
Noteworthy, HSC/LIC CD44 contributes to the establishment of
both BM niches.
CD44 Contributes to the Generation of the
BM Niches
The Contribution of CD44 to Matrix Assembly
Stem cells niches, including the osteogenic niche in the BM, are
particularly rich in HA (121). HSC synthesize and express HA,
and HA expression correlates with HSC adhesion to the endosteal
niche (122). Similarly, CD44 contributes to building an HA coat
on endothelial cells, which facilitates binding of mobilized HSC to
endothelial cells as well as HSC homing (123, 124). Furthermore,
perturbation in matrix components alters cell shape and intracel-
lular tension, which results in shifts in signaling events that affect
gene expression (125). This could be particularly important in the
BM niche, where HA delivery by HSC/LIC can induce expres-
sion of HA in niche cells (126). Furthermore, CD44 is involved
in matrix assembly (127) such that the HA–CD44 association
modifies the matrix to support colonization (128).
In concern about CD44v, there is evidence for an engagement
of CD44v6 in matrix assembly. A CD44v6 knockdown (kd) in
a highly metastatic tumor line revealed a striking reduction in
metastatic capacity, which was, at least, partly due to an altered
tumormatrix (81). CD44v6kd cells secrete amatrix not supporting
adhesion of CD44vwt or CD44v6kd cells, whereas both cells readily
adhere to the CD44vwt-matrix. In fact, HA synthase 3 (HAS3)
expression is strongly reduced in CD44v6kd cells (86), where high
HAS3 expression frequently correlates with aggressiveness of car-
cinoma and leukemia (129). On the opposite, the CD44v6kd cells
abundantly secrete hyaluronidase such that the matrix contains
a lower amount of HA and exclusively low molecular weight HA
(130), which significantly affects adhesion and the catcher activity
of the matrix (Figure 1A).
Briefly, HSC CD44 contributes to the generation of HSC niches
mostly via HA provision, where the composition of HA varies
depending on the expression of CD44v isoforms. CD44/CD44v
strengthensHAS3 expression and, by not yet definedmechanisms,
prohibits hyaluronidase activity.
CD44 Contributes to the Catcher Activity of the
Niche Matrix
CD44 is a transmembrane proteoglycan, which allows for the local
concentration of glycosaminoglycan-associating proteins (131).
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A B C
FIGURE 1 | The contribution of CD44 in HSC/LIC for assembly and
modulation of the osteogenic niche. (A) HSC secrete large amounts of HA.
Upon HA crosslinking, CD44 becomes activated, which supports transcription
of HAS3, which strengthens the process of high MW HA deposition and
incorporation of cytokines, chemokines, and proteases in the abundant HA
coat. (B) HSC quiescence and LIC proliferation are supported by the catcher
activity of CD44/CD44v6 and most pronounced CD44v3 associated GAG,
which bind a large range of cytokines and chemokines including HGF, bFGF,
OPN, and VEGF. (C) Particularly, LIC contribute to modulation of the matrix in
the osteogenic niche. This is due to CD44-HA initiated transcription of MMP2,
MMP9, uPAR, and cathepsinG. MMP2 and MMP9 bind to CD44; proMMP2 is
cleaved by CD44v6-associated MT1MMP, which concomitantly allows for focal
matrix degradation. CathepsinG and MMP9-activated TGFβ contributes to
bone resorption and niche preparation for LIC.
Of special interest for HSC and LIC is the binding of OPN to
CD44v3, CD44v6, andCD44v10 (47, 132, 133), whereOPN secre-
tion is further stimulated by HA (134). OPN is chemotactic and
haptotactic, and as such important for the recruitment ofHSC into
the niche (135). On the other hand, the OPN–CD44 interaction
exerts a feedback on the donor cell, which supports migration.
Thus, p53koCD44ko mice have the same rate of primary tumor
development as p53ko mice, but tumors do not metastasize (136).
Similarly, a blockade of CD44v10 strongly reduced OPN deliv-
ery by leukemic cells, which was accompanied by pronounced
retention of HSC in the niche (137). CD44v6 also binds VEGF
and HGF (44, 45, 138, 139). In the hypoxic environment of the
osteogenic niche, HIF1α acts as a regulator to prevent HSC pro-
liferation and exhaustion, where it is supported by VEGF, a target
of HIF1α (140). Instead, leukemic cells, which were supported
by VEGF-activated endothelial cells in the vascular niche, gain
in cytotoxic drug resistance (141). In concern about HGF, it is
worthwhile noting that a subpopulation of HSC responds to HGF
by migrating toward skeletal muscles (142). CD44v3 binds bFGF
that stimulates proliferation of underlying mesenchymal cells in
the developing limb and affects BM MSC (143, 144). This might
be due to bFGF inducing changes in HAS and hyaluronidase
isoform expression (145). A direct contribution of CD44v3-
bound bFGF to the activity of bone MSC remains to be explored
(Figure 1B).
Finally, CD44v6 can directly contribute to the composition
of the niche matrix (130). CD44v6 supports transcription of
hepatoma-derived growth factor, which stimulates the growth of
fibroblasts, endothelial cells, and vascular smooth muscle cells,
and recruits MSC (146). CD44v6 also promotes clusterin secre-
tion that influences chemokine secretion and initiates stromal
changes affecting intercellular communications (147). In addi-
tion, the complement (C) components 3a and 3b are absent in
a CD44v6kd matrix, but are abundantly delivered by CD44v6wt
cells (86). These findings are well in line with the innate immune
system, particularly C3, cooperating with CD44 in HSC to
strengthen the HSC CD44 – niche interaction [review in Ref.
(148)] (Figure 1A).
CD44 Modulates HSC Niches
CD44 concentrates MMPs at the cell surface, where the produc-
tion of uPAR, MMP2, and MMP9 is concomitantly stimulated by
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2355
Zöller Hematopoiesis, leukemia and CD44
the interaction between HA and CD44 (86, 149). MMP9 tran-
scription is actively supported by the CD44 intracellular domain
(ICD), which binds to aMMP9 promoter response element (150).
By a not yet defined mechanism, CD44v6 also is involved in
uPAR transcription (86). CD44 aggregation via HA binding facili-
tates MMP binding (150). Furthermore, proMMP2 becomes acti-
vated through CD44v-associated MMP14, which is located in the
leading lamella. As cell-bound MMPs are protected from their
inhibitors, this allows for focal degradation of the ECM to form
space for invading LIC (151). LIC also stimulate osteoclasts to
secrete cathepsinG and MMP9 to resorb bone to create a niche.
CathepsinG, primarily secreted by osteoclasts (152), is another
transcriptional target of HA–CD44 signaling (153). Transform-
ing growth factor β (TGFβ) activation through CD44-associated
MMP9 promotes angiogenesis, invasion (154), and enhances
osteoclast activity and bone resorption (155) (Figure 1C).
Taken together, HSC require a niche and CD44 contributes to
niche assembly. The most prominent CD44 contribution relies on
the stimulation of HA provision via pronounced HAS activation.
CD44 also supports retaining growth factors and chemokines
that are supplied by the different niche elements. This facil-
itates message delivery from the niche toward the HSC/LIC.
There is evidence for a contribution of CD44v particularly in
cytokine/chemokine retention. It remains to be explored whether
this provides a pronounced profit from the niche for CD44v
expressing LIC. CD44 also contributes to modulating the niche
by hyaluronidases and proteases that transcription is promoted
by CD44 or that become activated via direct or indirect associ-
ations with CD44. There is no evidence that LIC contribute to
establishing a niche. Rather, LIC are suggested to make use of the
HSC niche. It is still disputed whether LIC displace HSC from
their niche or actively remodel/destroy the niche (156), such that
HSC die by neglect. High hyaluronidase secretion by CD44v6+
LIC could favor the latter.
CD44 Supports Adhesion, Homing, and Migration
of HSC and LIC
CD44, HSC, and LIC Adhesion to the Bone Marrow
Stroma
One of the prime functions of the osteogenic niche is the retention
of HSC to instruct for longevity and quiescence, which requires
firm HSC adhesion. This task is mainly taken over by HA (157).
HA binding initiates or, at least, influencesmost activities of CD44
(158). The importance of CD44 as an adhesion molecule for HSC
and LIC has been amply demonstrated (157, 159). The particular
engagement of the CD44–HA interaction was confirmed by the
finding that HSC adhesion can be blocked by anti-CD44, soluble
HA, or hyaluronidase (160).
CD44 adhesion to its ligand(s) induces up-regulation of addi-
tional adhesion molecules, mostly integrins, which strengthen
HSC adhesion (161). This was intensely explored for the asso-
ciation of CD44 with α4β1 (162, 163). Upon activation by HA
adhesion, the two molecules directly associate (164), which is
accompanied by α4β1-promoted stronger adhesion to FN and
laminin (165). HSC α4β1 additionally supports the direct contact
with stroma cells via ICAM1 binding (166). In line with the
contribution of CD44 and α4β1 to the adhesion of HSC to the
osteogenic niche, anti-CD44 and anti-α4β1 dislodge HSC from
the BM niche (167, 168) (Figure 2A).
CD44 also participates in LIC embedding into the endosteal
niche, such that targeting CD44 is considered a new strategy to
eliminate persistent and drug-resistant LIC. In AML, CD44 is
required for the transport of LIC to theHSC niche, and anti-CD44
antibodies alter the fate of the LIC by inducing differentiation
(101). In a mouse model of CML, BCR-ABL1-transduced progen-
itors from CD44-mutant donors were defective in BM homing,
which resulted in decreased engraftment and impaired CML-
like disease induction (100). These studies provided additional
evidence that LICmay bemore dependent onCD44 for settlement
in the osteogenic niche thanHSC (101). Studies in amurinemodel
confirmed leukemia cell homing and growth retardation by a
CD44-specific antibody (169). However, during reconstitution, a
panCD44-specific antibody more efficiently interfered with HSC
than leukemia cell settlement in the BM niche (82).
The latter topic, how to avoid replacement of HSCwhen attack-
ing LIC, was recently approached in an elegant study aiming to
find selective ligands for LIC in CML and AML. Alteration of
the niche by osteoblastic cell-specific activation of the parathy-
roid hormone receptor attenuates BCR-ABL1 oncogene-induced
CML-like myeloproliferative neoplasia, but enhances MLL-AF9
oncogene-induced AML, possibly through opposing effects of
increased TGF-β1 on the respective LIC. These results, though
providing a first and very important hint toward sparing niche
embedded HSC, also demonstrate that niches differ for distinct
LIC (170). The use of CD44v specific antibodies could be an alter-
native for blocking LIC, but sparing HSC embedding in the niche.
Unfortunately, our data so far point toward a dominating role of
CD44s in niche embedding. Thus, adhesion of CD44v6/v7ko and
of CD44v7ko HSC to BM-Str is unimpaired (97, 171).
Facing competition for the niche, it should be remembered that
LIC might remodel the niche such that it no longer serves the
requirements of HSC (172). This possibility did not yet receive
appropriate attention. Nonetheless, growing awareness and elab-
oration of the differentiation potential of distinct SC populations,
particularly of BM derived MSC, might finally allow reconstitut-
ing/replacing a niche, which was distorted by LIC.
Distinct to the contribution of HSC/LIC CD44 on adhesion,
little is known on the engagement of stroma cell provided CD44.
Anti-CD44v6 strikingly hampered stroma formation in rat long-
term BM cultures, but had no impact on HSC embedding in
a preformed stroma (173). In addition, recovery of HSC from
wt mice in the BM of CD44v7ko mice is severely impaired (97).
In vitro studies confirmed that HSC poorly adhere to long term
CD44v6/v7ko and CD44v7ko BM-Str (171, 174). Thus, BM-Str
CD44 should not be neglected as it contributes tomatrix assembly.
A comprehensive evaluation is missing. However, the availability
of conditional ko mice will facilitate answering the question.
There is overwhelming evidence confirming the important
finding of Miyake that HSC require CD44 for embedding in the
BM niche, and that dislodgement by anti-CD44 severely affects
hematopoiesis. In view of the essential role of CD44 to anchor
HSC in the osteogenic niche, care should be taken on the ther-
apeutic use of anti-CD44 to drive LIC out of the niche. Despite
promising results, further refinement is required to guarantee
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2356
Zöller Hematopoiesis, leukemia and CD44
P-selectin
E-selectin
HSC
HSC
endothelial cell
SDF1
LIC
CXCR4
CD44
HSC
HA
CD44 and transferred HSC extravasation CD44 and transferred HSC homing
1
vascular niche
fibronectin
ICAM
VCAM
CD44 and HSC / LIC adhesion CD44 and HSC mobilization
activ.Mφ
G-MCSF
G-MCSF-R
=
CAR
SDF1
HSC
G-MCSF
activation
CD26
MMP9
cathepsin
neutroph elastase
SDF1 degradation
fibronectin degradation
MT1MMP
osteoblast
p
1
1
5
R
h
o
G
E
F
RhoA
GEM
GDP > GTP
P
ROK
F-actin
s
rc
FAKP
α 4 β1
PKA
p
a
x
il
li
n
Rac
PKC
ADAM17
Presenilin-2 /
γ-secretase
complex
nucleus
CD44ICD
CBP/p300
CD44
A B
C D
α4β1
FIGURE 2 | CD44-mediated adhesion, mobilization, migration, and
homing in HSC/LIC. (A) HSC and LIC adhesion to the HA-rich endosteal
niche is supported by α4β1, which binds to fibronectin and via ICAM to
osteoblasts. CD44-associated CXCR4 binding to stroma-derived SDF1 is of
major importance in retaining HSC in the osteogenic niche. One of the
adhesion strengthening signaling pathways proceeds via the
CD44-crosslinking initiated activation of ERM and ankyrin, which includes
activation of a RhoGEF that interacts with RhoA and stimulates ROK. This
strengthens ankyrin phosphorylation and the F-actin linkage. (B) To interfere
with the retention of HSC in the osteogenic niche for PBL-HSC
transplantation, adhesion requires to be loosened. This is achieved by
blocking CD44 and/or α4β1, and most commonly by G-MCSF that binds to
BM-Mϕ, which leads to activation of several proteases that degrade SDF1 and
fibronectin. In addition, CAR become attacked and secrete less SDF1. Finally,
G-MCSF leads to CD44-associated MT1MMP activation in HSC. By the CD44
cleavage, the adhesion of HSC becomes further reduced. (C) Homing of
transferred HCS is facilitated by the constitutive expression of P-selectin and
L-selectin on BM endothelial cells. CD44 binds to the selectins and α4β1
binds to VCAM-1, which supports loose attachment and rolling.
CD44-promoted HA secretion further slows down HSC rolling and allows for
extravasation. HA binding initiates activation of CD44, such that it binds to the
cytoskeletal linker proteins ankyrin and/or ERM, which link CD44 to F-actin.
CD44 moves from the trailing edge to the leading lamella such that the
process of extravasation is initiated, where the activation-induced association
with integrins plays an essential role. (D) It is discussed that the transient
cleavage of CD44 by ADAM17 and liberation of the cytoplasmic tail (CD44ICD)
by presenilin2/γ-secretase facilitates departure from the endothelium of the
BM vasculature. CD44ICD acts together with CBP/p300 as a transcription
factor, besides others for CD44. Via this feedback, regain of CD44 allows for
HSC adhesion in the osteogenic niche after arrival.
unimpaired hematopoiesis. First trials to replace anti-CD44 have
been successful, but point toward no single strategy being effective
in distinct LIC. Additional studies are also needed to elaborate
options for correcting niches, which were distorted by LIC.
CD44 and HSC Mobilization
Transplantation of hematopoietic progenitor cells provides in
many instances an ultimate chance of curative leukemia therapy.
It has become obvious that the transfer of peripheral blood HSC
appears advantageous, yet it requires HSC mobilization. In 1976,
Richman et al. described an increase of HSC in the blood of
patients, who had undergone chemotherapy (175). Later, a similar
increase was observed after the administration of recombinant
growth factors (176). In fact, both G-CSF and chemotherapy
mobilize HSC through the samemechanisms, with chemotherapy
increasing the level of endogenous G-CSF (177). Though the
precise mechanism remains to be elucidated, HSC mobilization
obviously does not proceed directly, as HSC do not express the
G-CSF receptor, which is expressed by BM macrophages (Mϕ)
(178). Activation of Mϕ could result in a reduction of Nes+ MSC
and SDF1-abundant reticular cells (CAR), and their provision of
SDF1 such that the SDF1-CXCR4 bond becomes loosened (179,
180). SDF1 is secreted by several BM-Str and its interaction with
CXCR4 on HSC plays a key role in retention and trafficking.
CXCR4 expression is enhanced through signaling cascades involv-
ing cAMP, PI3K, several GTPases, and PKCζ (181). PKCζ induces
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motility, adhesion and survival, and MMP2 and MMP9 secretion
(182). Disruption of the SDF1-CXCR4 axis is the major mecha-
nism leading to HSC release from their niche (182, 183). Alterna-
tively, not mutually exclusive, upregulated expression of proteases
may be involved, which can affect SDF1 (184) via MMP9 (185)
or CD26 (186), cathepsin G and K, and neutrophil elastase (183).
The same proteases also may account for VCAM1, FN, and OPN
degradation (187). In addition, CD44 cleavage via MMP14 can
contribute to HSC mobilization, where G-CSF leads to increased
MMP14 expression inHSC (188, 189). Activation of the C cascade
and plasminogen also contributes to HSCmobilization (190, 191)
(Figure 2B).
Although G-CSF efficiently mobilizes HSC in most instances,
some patients do not or insufficiently respond. In addition, G-
CSF treatment may by accompanied by maturation of the most
primitive progenitors, and this impairs HSC homing and recov-
ery of hematopoiesis. Therefore, additional approaches for HSC
mobilization have been searched for, in particular, mobilization
via a blockade of adhesion molecules expressed by CD34+ cells.
As described above (167, 168), concomitant application of anti-
CD44 and anti-α4β1 most efficiently mobilizes HSC. Notably,
most of themechanisms suggested accounting forG-CSF-induced
HSC mobilization might become initiated directly via the CD44
blockade. First, as CD44 is associated with CXCR4, SDF1-CXCR4
binding becomes loosened by a CD44 blockade (192). Sec-
ond, antibody crosslinking of CD44 contributes to the activa-
tion of MMP9 and MT1MMP, which both are associated with
CD44 (193).
In brief, mobilization, though mostly approached via G-CSF,
can be achieved by directly loosening adhesion ofHSC to the niche
via anti-CD44 and/or anti-α4β1.
CD44 and HSC Homing
With the therapeutic transfer of mobilized HSC, the question
arose on their homing. Transferred HSC preferentially home
into the BM, where they search for the osteogenic niche (194).
Homing is facilitated by the unique feature of BM endothelium
that constitutively expresses the endothelial P- and E-selectins
and VCAM1 (195). Proinflammatory cytokines stimulate CD44
expression in endothelial cells and strengthen their binding to
HA. This promotes the arrest of HSC, which bind via CD44 to
HA captured by endothelial cells (196). HSC express P-selectin
ligands and CD44 as well as VCAM1 receptors such as α4β1
(197–199). Function blocking antibodies and targeted deletions
confirmed the contribution of these adhesion molecules to slow-
down HSC, which allows for firm adhesion and extravasation
(200, 201) (Figure 2C).
CD44 also is involved in the extravasation of the endothelial
cell-attached HSC (202). CD44–HA binding initiates the inter-
action of the CD44 cytoplasmic tail with the actin cytoskeleton
through ankyrin and ERM proteins (196, 203), guiding CD44
to the leading edge of migrating cells (204). Thus, cells express-
ing CD44 with a truncated cytoplasmic tail retain HA-binding
capacity, but loose the capacity to migrate on HA (204). One of
the central events in CD44-mediated cytoskeletal reorganization
appears to be Rac1 activation. Lamellipodia formation on HA-
coated plates can be inhibited by a CD44 blocking antibody,
but also by transfection of a dominant-negative mutant form of
Rac1 (205). Upstream regulators of Rac1 are Vav1 and Vav2,
phosphotyrosine-dependent guanine exchange factors of Rho
GTPases. Vav phosphorylation is mediated by src kinases (206).
As GEM-located CD44 associates with src (207), cytoskele-
ton reorganization most likely is initiated via src activation.
Another mediator of CD44 signaling is RhoA. The RhoA-specific
p115RhoGEF interacts with CD44 and regulates HA-mediated
CD44 signaling via the serine-threonine Rho-Kinase (ROK), a
downstream target of RhoA. ROK phosphorylates CD44, which
promotes enhanced ankyrin binding (208). Another pathway
of CD44 promoted motility proceeds via the association with
α4β1. By associating with α4β1, CD44 gains access to FAK
(focal adhesion kinase) and α4β1 gains access to src kinases and
ERMproteins, such that the integrin–paxillin association becomes
weakened and the GEM-integrated CD44-ezrin-integrin-FAK
complex moves toward the leading edge (164, 209).
Cell motility is additionally supported by CD44 cleavage via
a disintegrin and metalloproteinase domain (ADAM) protein
and MMP-14 (210). CD44 cleavage is stimulated by Ca++
influx, which triggers ADAM10 activation after proADAM10
dissociation from calmodulin. ADAM17, which colocalizes with
CD44 at Rac-regulated membrane ruffling areas, becomes acti-
vated by PKC and Rac and contributes to CD44v cleavage
(211, 212). Thus, the rapid activation of membrane-integrated
proteases by CD44–HA binding contributes to a shift toward
motility by CD44 cleavage. CD44 cleavage is tightly regulated,
in part, by the missing activation of CD44-associated pro-
teases after CD44 cleavage, and in part by cleavage-promoted
CD44 transcription. After ectodomain cleavage, CD44 becomes
accessible to the presenilin/γ-secretase complex, which trig-
gers intramembrane CD44 cleavage, setting free the CD44
ICD (CD44-ICD). CD44-ICD acts as a cotranscription factor
that potentiates CD44 (28), MMP9, and MMP3 transcription
(150)(Figure 2D).
As leukemia therapy frequently relies on autologous HSC
transplantation, it became important to know whether LIC
compete with HSC not only for the niche but also for hom-
ing. The described signaling pathways promoting HSC extrava-
sation do not fundamentally differ for LIC. However, there
are subtle differences. This was explored in an elegant study
for BCR-ABL1-induced CML-like myeloproliferative neoplasia.
Expression of α4β1, α5β1, LFA1, and CXCR4 did not differ
between BCR-ABL1(+) progenitors and HSC, but expression of
P-selectin glycoprotein ligand-1 and of -selectin was lower than
in HSC. Deficiency of E-selectin in the recipient BM endothe-
lium significantly reduced engraftment by BCR-ABL1-expressing
SC. Destruction of selectin ligands on leukemic progenitors by
neuraminidase reduced engraftment. BCR-ABL1-expressing -
selectin-deficient progenitors were also defective in homing and
engraftment, and an -selectin-specific antibody decreased the
engraftment of BCR-ABL1-transduced SC. These results establish
that BCR-ABL1(+) LIC rely to a greater extent on selectins and
their ligands for homing and engraftment than HSC. Thus, a
selectin blockade may be beneficial in autologous HSC transplan-
tation for CML and perhaps other leukemia (213).
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After extravasation, transplanted HSC should reach the
osteogenic niche. As mentioned, HSC synthesize HA (214), and
HA expression supports HSC migration toward the endosteal
niche (189). In the endosteal niche, SDF1 promotes adhesion
through CD44-associated CXCR4 accompanied by rac1 and
cdc42 activation (182, 192, 215). These findings confirm the key
role of HA and CD44 in SDF1-dependent HSC anchorage within
specific niches (189). Finally, space is created by activated ROK,
which phosphorylates the Na-H-exchanger1. Hyaluronidase-2
and cathepsinB become activated in the acidic milieu and support
ECM degradation (206, 207).
Unfortunately, AML share the homing mechanisms with HSC
(216, 217). However, the problem can possibly be circumvented
in leukemia highly expressing CD44v6, as CD44v6 expression is
low in HSC and HSC homing is dominated by CD44s. Analyz-
ing migration of HSC from CD44v6/v7ko and CD44v7ko mice
toward HA and BM-Str revealed impaired migration toward FN,
possibly due to CD44v6 directly binding to FN (218) or being
promoted by the CD44v6-α4β1 association (174). Furthermore,
HSC migration toward IL6 is strikingly impaired by anti-CD44v6
(219). Migration of CD44v7ko and CD44v6/v7ko HSC toward
SDF1 was reduced to background levels, which indicates major
importance of these two splice variants in migration along a
SDF1 gradient (220). Binding and migration toward OPN is also
impaired in CD44v6/v7ko HSC. The finding fits the selective
CD44v6 binding of OPN, which triggers migration and invasion
(221, 222). Finally, BM-Str CD44v7 supports HSC migration
(97). Thus, CD44v6/v7 are engaged in HSC migration toward
chemokines/cytokines and BM-Str. Another protein selectively
trapped by CD44v6 is C3 (81, 130). As elegantly elaborated by the
group of Ratajczak [review in Ref. (223)], C3 can drive CXCR4
into lipid rafts, where it associates with CD44v6. Thereby, the
CXCR4–SDF1 axis becomes strengthened, which helps retain-
ing HSC in the niche. In a similar attempt elaborating homing
of multiple myeloma to the BM, the authors explored differ-
ences in a stroma-dependent and a stroma-independent line.
Only the stroma-dependent line expressed IGF-1R and CD44v6,
where IGF-1 promoted chemotaxis toward BM-Str and CD44v6
supported adhesion. By modulating the culture conditions, the
authors demonstrated that BM-Str promotes up-regulation of
IGF-1R and CD44v6 in multiple myeloma, which facilitate hom-
ing and support adhesion to BM-Str (224).
Thus, the particular BM endothelium supports the egress of
transplantedHSC into the BM. The engagement of CD44 relies on
the provision ofHAand the binding ofCD44 to -selectin, binding
being supported by the association with integrins. Once attached
to the endothelium, CD44 promotes activation of rac and rho,
which initiate the shift toward a migratory phenotype. Migration
is strengthened by activation of CD44-associated proteases. The
proteases create space and cleave adhesion molecules including
CD44, which fosters migration toward the endosteal niche. Settle-
ment in the niche follows the path that underlies the preferential
retention of HSC in the osteogenic niche. In most instances, LIC
andHSCuse the same adhesionmolecules and signaling pathways
for migration. Nevertheless and notably, there are some discrete
differences between HSC and LIC, which may help elaborating
protocols for preferential homing of transplanted HSC.
CD44 and the Crosstalk Between HSC and
the Niche
CD44 does not only contribute to niche assembly but, impor-
tantly, there is a feedback from the niche toward HSC and LIC,
which also involves CD44. Two aspects of this crosstalk will be
in focus, the engagement of CD44 in (i) HSC quiescence and (ii)
stress resistance, which both are linked to the osteogenic niche.
Different to the engagement of CD44 in HSC and LIC homing
and migration, mostly HSC rely on CD44-promoted quiescence.
Instead, both HSC and LIC profit from CD44 in apoptosis resis-
tance. Though the CD44-mediated crosstalk with the niche and
the GEM location of CD44 are important for HSC and LIC apop-
tosis resistance (225, 226), the dominating mechanisms differ.
In advance of discussing the impact of the niche on CD44-
promoted quiescence and apoptosis resistance, exosomes need to
be mentioned. Unfortunately, their impact on HSC and LIC has
not yet been explored in detail. Many cells including HSC and
LIC secrete small vesicles, called exosomes, which are supposed to
be most efficient intercellular communicators (227–229), where
miRNA transfer via exosomes can lead to target cell reprogram-
ming (230). This was demonstrated for ESC exosomes repro-
gramming hematopoietic progenitors through miRNA delivery
(231), and for the transfer of miRNA between different cells
of the hematopoietic system as well as from CIC into BM-Str
(232). Although the impact of CD44 on the exchange of exo-
somal miRNA between HSC/LIC and niche cells has not been
elaborated, the impact of exosomal CD44v6 on miRNA transfer
points toward the engagement of CD44 (78) and unquestionable
demonstrated the strong impact of exosomal miRNA. Thus, a
more comprehensive knowledge on the transfer of HCS exosomal
miRNA should be approached, and can be expected to open new
therapeutic options.
CD44 and HSC Quiescence
The quiescent state is critical for preserving self-renewal capac-
ity and stress resistance of HSC. Besides intrinsic regulatory
mechanisms, where p53 plays a dominant role, there are extrin-
sic microenvironmental regulatory mechanisms, which include
angiopoetin-1, TGFβ, bonemorphogenetic proteins (BMP), TPO,
N-cadherin, integrins, Wnt/β-catenin, and OPN (233).
Angiopoietin is secreted by osteoblasts and binds to Tie2 on
HSC, which supports maintenance of quiescence and prevents
cell division. Furthermore, the Tie2-angiopoietin interaction pro-
motes cobblestone formation in long-term BM cultures (234).
Besides strengthening adhesion of HSC to BM-Str (234), possibly
via CD44, I am not aware of a particular linkage between the
angiopoietin-Tie2 axis and CD44 signaling.
TGFβ are potent inhibitors of HSC proliferation. TGFβ dis-
ruption increases circulating progenitor cells, and a bolus injec-
tion of TFGβ1 inhibited early progenitor proliferation. TGFβ-
mediated quiescence of HSC may be due to alteration in cytokine
receptor expression and upregulation of cyclin-dependent kinase
inhibitors (235). The engagement of CD44 relies on its interaction
with the TGFβR1 (236). TGFβ cooperates with HA-activated
CD44 to induce expression of the NADPH oxidase (237), which
could help regulating redox signals in HSC.
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Bone morphogenetic proteins, secreted by osteoblasts (238),
potently inhibit HSC proliferation. BMP bind to their serine
threonine kinase receptors on HSC, which leads to transphos-
phorylation and kinase domain activation, initiating phospho-
rylation of Smad 1, 5, and 8 that concomitantly associate with
Smad4 and translocate to the nucleus. In the nucleus, they act
as cotranscription factor regulating expression of target genes
such as Runx1 and GATA2, which operate during specification of
hematopoiesis (239) and regulate HSC quiescence (110, 240, 241).
The linkage to CD44 is based on the association of CD44 with
Smad1 (242). Alternatively, and BMP-independent, Smad1 can
become phosphorylated via galectin-9, where galectin-9 binding
to CD44 promotes formation of a CD44/BMP receptor complex
with concomitant BMP receptor activation (243).
Binding of TPO to its ligand (MPL) is critically involved inHSC
steady-state maintenance with an over 150-fold reduction of HSC
in TPOko mice. Posttransplantation HSC expansion was highly
MPL-and TPO-dependent. Accelerated HSC cell-cycle kinetic in
TPOko mice is accompanied by reduced cyclin-dependent kinase
inhibitor p57Kip2 and p19INK4D expression (244). The activity of
TPO becomes strengthened by glucosaminoglycans in the matrix.
Though this was demonstrated for megakaryocytopoiesis (245),
it may have bearing on TPO affecting HSC embedded in the
osteogenic niche.
Wnt signaling has emerged as an important factor in HSC
quiescence, self-renewal, and differentiation (246). Wnt, secreted
glycoproteins, binds to their sevenpass transmembrane receptors
(Frizzled) (247) and low-density lipoprotein receptors LRP5 and
LPR6 (248), which become phosphorylated and form an acti-
vated Frizzled/LPR receptor complex. The Frizzled/LPR recep-
tor complex promotes dephosphorylation of β-catenin, which
in the absence of Wnt signaling is phosphorylated and associ-
ated with a so-called destruction complex (249). Dephosphory-
lated β-catenin translocates to the nucleus, and together with
LEF/TCF initiates transcription of Wnt target genes. In the non-
canonical pathway, mostly Wnt5a signals via Frizzled using as
coreceptor ROR, which leads to RhoA/Rac and JNK activation.
In the Wnt–Ca++ pathway, G-protein signaling is activated with
upregulation of IP3-mediated release of intracellular Ca++ and
activation of PKC, which triggers nuclear translocation of NFAT
and NFκB (246). Though Wnt is a potent morphogen (250),
Wnt effects are highly context and dose-dependent (251), which
makes it difficult to define precisely its role in HSC maintenance.
To circumvent these difficulties, the group of Scadden used an
osteoblast-specific promoter for expression of the Wnt panin-
hibitor Dickkopf1 (Dkk1). Binding to the coreceptor LRP5/6 leads
to internalization of the complex (252). Inhibition of Wnt signal-
ing in HSC resulted in reduced p21Cip1 expression, increased cell
cycling, and a continuing decline in the reconstitution capacity of
HCS. Notably, though the effect on HSC was microenvironment-
dependent, HSC did not recover, when transferred in a normal
host (253). Furthermore,Wnt-inhibition affected activation of the
Notch target, Hes-1. This finding suggests that Notch and Wnt
coordinately regulateHSC quiescence. Indeed, elevatedHes-1 and
p21 expression correlate with the maintenance of HSC quiescence
(254). The importance of Notch signaling was confirmed by inhi-
bition of Notch signaling diminishing the capacity of HSC to
maintain an undifferentiated state. As proliferation and survival
were not affected, the authors suggest that Notch “may act as a
“gatekeeper” between self-renewal and commitment” (255).
Wnt signaling, in fact, is not only important for HSC [review in
Ref. (62)], but the association of CD44 with Wnt signaling is also
amply demonstrated for LIC [review in Ref. (61)]. However, as
mentioned, Wnt effects are context dependent. Highlighting the
differences to HSC, one example will be given. The cytoplasmic
domain of GEM-located CD44 associates with the Wnt receptor
LRP6, whereby LRP6 becomes recruited into the plasma mem-
brane, which strengthens Wnt signaling and the accumulation of
β-catenin in the nucleus, where down- and upregulation of CD44
directly affectedWnt signaling. Importantly, this activity of CD44
does not require CD44-HA crosslinking (256).
Osteopontin also negatively regulates the number ofHSC in the
BMniche.OPNko mice display a significantly increased number of
HSC, but not of committed progenitors (257). OPN also canmod-
ify primitive hematopoietic cell number and function in a stem
cell–non-autonomous manner. This conclusion derived from the
observation that the BM microenvironment of OPNko mice was
sufficient to increase the number ofHSC, whichwas accompanied
by an increase in stromal Jagged1 and angiopoietin-1 expression
and a reduction of primitive hematopoietic cell apoptosis (116).
The authors discuss that the ECM plays a dynamic role in govern-
ing HSC responsiveness to expansion signals.Whether the signals
are transferred via CD44-associated integrins (258) or directly via
OPN binding to CD44 (133) remain to be explored. Instead, OPN
binding to CD44v6 in CIC promotes activation of the PI3K/Akt
pathway and promotes tumor growth (259). This is mentioned to
remember that in concern of signal transduction, the peculiarities
of HSC frequently do not allow a direct comparison to oncogene
transformed CIC or LIC.
Finally, the interaction of SDF1, expressed by developing
stroma in fetal bones, with HSC CXCR4 is critically for retaining
HSC in the quiescence-protecting niche (260). Originally, it was
noted that SDF1ko and CXCR4ko embryos have greater impair-
ment of myelopoiesis in the BM than in the fetal liver, which
suggested that SDF1 and CXCR4 are primarily involved in colo-
nization of the BM byHSC during embryogenesis (261). Later on,
elegant work with conditional CXCR4ko mice implicated stromal
SDF1 and its receptor in maintaining the pool of quiescent HSC.
Conditional CXCR4ko mice have a significantly increased pool of
HSC in G1 compared to wt mice. This may be due to an altered
environment with upregulation of cytokines, which promote HSC
cycling and differentiation (115). Interestingly, actively signaling
CXCR4 is associated with GEM localization (262). This implies
that CXCR4 signaling sensitivity can be modulated by colocal-
ization with other signaling molecules, including Rac1 (263).
Notably, HA-crosslinked, GEM-located CD44 directly interacts
with CXCR4, such that SDF1–CXCR4 signaling is abrogated in
CD44kd cells (264). Less is known about the impact of the niche
on the resting versus cycling state of leukemia. However, it can
be expected that due to oncogene transformation LIC are less
susceptible to quiescence promoting signals from the niche ormay
even distinctly respond.
Figure 3 summarizes those signaling pathways in HSC, where
CD44 is actively involved in maintaining HSC quiescence and
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FIGURE 3 | CD44 imparts quiescence and oxidative stress
protection in HSC. HSC quiescence and oxidative stress resistance
are partly cell-autonomous processes, but are supported by a variety of
interactions with BM-Str derived factors, where CD44 comes into play
by its linkage and activation via HA binding as well as by its association
with a variety of growth factor and chemokine receptors such as
LRP5/6, CXCR4, Tie2, the TGFβR1, BMPRs, and α4β1. Only those
signal transduction pathways and transcription factor activation/nuclear
localization are shown, where HSC CD44 plays a major role. Notably,
CD44ICD is suggested to be an important cotranscription factor for
HIF-1a, the major regulator to cope with the low oxygen in the
osteogenic niche.
HSC stress protection. Thus, CD44 becomes stimulated by several
key molecules engaged in HSC quiescence. Alternatively, CD44,
particularly when crosslinked by HA, associates with quiescence
regulating molecules.
Last, not least, the importance of the CD44–HA interaction
was also demonstrated with HAS3ko mice. HSC homing into the
osteogenic niche depends on the HA coat of endothelial cells, and
is significantly retarded in HAS3ko mice (265). Furthermore, HA
is required for the generation of HSC during differentiation of
ESC (266). Finally, HSC seeded onHA rarely proliferate and retain
multipotency (267, 268). All these findings strengthen the upmost
importance of the CD44–HA crosstalk in HSC maintenance.
CD44 and HSC Stress Resistance
The distinction between HSC and LIC also accounts for a second
phenomenon, the response to low oxygen pressure according
to the location of HSC in niches (110), characterized by low
oxygen concentration (269). Though LIC compete with HSC for
the niche, they are not dependent on low oxygen and instead
remodel the niche toward accumulation of inflammatorymyelofi-
brotic cells, which drive LIC expansion, but compromise HSC
maintenance (270). Notably, too, the metabolic status of HSC
residing in a hypoxic BM environment also differs from that of
their differentiated progeny (271).
Hematopoietic SC maintains redox homeostasis by low oxy-
gen production due to the minimal metabolic rate (271, 272).
Low metabolic rate maintenance further relies on asymmetric
cell division, where the daughter cell, which remains in the SC
state, inherits a very low level of energized mitochondria (273,
274). Furthermore, HSC generate energy mainly via anaerobic
metabolism maintaining a high rate of glycolysis, which limits
the production of reactive oxygen species. The hypoxia respon-
sive regulatory pathways in HSC resembles that in other cells,
HIF1α being the master regulator driving the metabolic machin-
ery toward anaerobic glycolysis (275). HIF1α, stabilized under
hypoxic conditions (276), reprograms glucose metabolism via
transcriptional activation of genes encoding glucose transporters,
glycolytic enzymes, and metabolic regulatory enzymes, thereby
switching from oxidative to glycolytic metabolism (277). One
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of the mechanisms proceeds via the HSP GRP78 and its lig-
and Cripto, HIF1α binding to the Cripto promoter (278). The
importance of HIF1α orchestrating molecular responses, which
maintain redox homeostasis in the face of changing O2 levels,
was demonstrated by the loss of reconstitution capacity of HSC
in HIF1αko mice (279). HSC dispose on additional regulatory
molecules, including polycomb, DNA damage-related, and anti-
oxidant proteins that participate in ROS regulation (280). Notably,
maintenance of the hypoxic state of HSC is not restricted to the
location in a poorly vascularized niche, but is dictated by cell-
specific mechanisms derived from their glycolytic metabolic pro-
file (281). Finally, the cotranscription factor CD44–ICD promotes
expression of HIF2α (282), as well as of additional hypoxia-
related genes, like aldolase c, 6-phosphofructose-2-kinase, pyru-
vate dehydrogenase kinase-1, and pyruvate dehydrogenase, which
are directly associated with aerobic glycolysis (283–285). The
authors point out that the repeatedly observed impact of the
CD44-ICD on HIF expression in SC suggests a more active role
of CD44-ICD in SC maintenance and protection as previously
anticipated (282).
In concern about the engagement of CD44 and its ligands in
protection from oxidative stress, it also was described that neural
SC reside undifferentiated in a HA richmatrix, but proliferate and
differentiate upon hyaluronidase upregulation (286). Additional
contributions of CD44 andHA on stress protectionmay be shared
by HSC and LIC and are described below.
Taken together, HSC circumvent stress, which would drive
them into proliferation and exhaustion, mostly by a mini-
mal metabolic rate and the generation of energy via anaerobic
metabolism. The main contribution of CD44 relies on the cotran-
scription factor activity of CD44-ICD.
CD44, LIC, and Apoptosis Resistance
Besides contributing to circumvent stress, CD44 also actively pro-
motes apoptosis resistance. From this activity ofCD44,which does
not appear to be of major importance for HSC stress resistance,
LIC make profit. As to my knowledge, CD44-mediated apoptosis
resistance proceeds in LIC and CIC via overlapping pathways,
some examples of CIC will be included, where corresponding
experiments have not yet been performed with LIC. There are
two major mechanisms of CD44-mediated apoptosis protection:
(i) initiation of signal transduction by CD44 crosslinking via HA,
which frequently involves CD44v and associated RTK (287), and
(ii) the crosstalk of CD44withmultidrug resistance genes that also
is HA-dependent (288).
Apoptosis resistance initiated by the cooperation of CD44- or
CD44v with RTKmostly proceeds via activation of anti-apoptotic
proteins. CD44 coimmunoprecipitateswith all ERBB familymem-
bers. The association of CD44 with ERBB2 and ERBB3 mediates
heterodimerization and activation of the receptor in response to
neuregulin, which strongly promotes CIC apoptosis resistance
(289, 290). The impact of CD44 on ERBB2 activation is strik-
ingly HA-dependent. CD44 crosslinking via HA initiates asso-
ciation of CD44 with ERBB2, which becomes phosphorylated.
The complex, located in lipid rafts, includes ezrin, the chaperones
HSP90 and CDC37, and PI3K, which accounts for drug resistance
via activation of anti-apoptotic proteins. Apoptosis resistance
is not seen when the HA–CD44 interaction is blocked, which
causes complex disassembly and inactivation of ERBB2 (291).
The authors also unraveled activation of an ERBB2-PI3K/Akt-β-
catenin axis, which contributes to COX2 expression and COX2-
promoted suppression of caspase3 activation. The data argue for
a feedback loop, whereby COX2 strengthens HA production and
promotes prostaglandin E2 expression (292). An additional feed-
back loop proceeds via formation of the ERBB2/ERBB4–CD44
complex, which via ERK activation promotes HA production by
HAS1, -2, and -3 phosphorylation/activation (293) (Figure 4A).
Another, well-known pathway of apoptosis resistance involves
the CD44v association with MET, which is initiated by HGF
binding to CD44v3 or CD44v6 (138, 294), and promotes MET
phosphorylation. MET phosphorylation requires the cytoplasmic
tail of CD44 and the interaction with ERM proteins for activation
of the Ras-MAPK pathway (294). CD44v6 binding to the ECM
also activates the PI3K-Akt pathway andWnt/β-catenin signaling
(130, 295) and regulates MET transcription (86, 296). Similar
observations account for insulin-like growth factor-1 receptor and
PDGFR activation through HA-stimulated CD44 in transformed
cells (133, 297, 298) (Figure 4A).
Importantly, CD44v6 promoted apoptosis resistance can also
rely on the association of GEM-located CD44v6 with FAS. This
association prevents trimerization of FAS upon ligand binding.
Notably, apoptosis susceptibility strongly increases by a blockade
of CD44v6 (299). Promoting FAS trimerization by a CD44v6
antibody blockade presents a new and interesting option in the
therapy of CD44v6 expressing leukemia.
The interaction between CD44 and RTK can also proceed via
proteases. CD44v3 binds the proform of the heparin binding
epidermal growth factor (HB-EGF), which is cleaved by CD44-
recruited MMP7. Cleaved HB-EGF binds and activates ERBB4,
which signals for cell survival (300, 301). The interaction of
CD44 with MMP9 leads to apoptosis protection independent of
RTK. CD44 and MMP9 expression are interdependent (149), and
in CLL patients with poor prognosis CD44, CD49, and MMP9
are physically associated (302, 303). CD44-associated MMP14
accounts for proMMP9 cleavage (191). Activated MMP9 can
interfere with TGFβ activation, whereby several mechanisms of
TGFβ-promoted apoptosis become silenced (304, 305).
An additional pathway of CD44-promoted resistance to reac-
tive oxygen- and cytotoxic drug-induced stress under physio-
logical and pathological conditions proceeds via the mammalian
Hippo signaling pathway. In the resting state, CD44-associated
merlin accounts for JNK, p53, and p21 upregulation, and YAP as
well as ciAP1/2 downregulation, which jointly promote caspase3
activation and apoptosis. When CD44 becomes activated by HA
binding, merlin is phosphorylated and dissociates from CD44.
In the absence of merlin, CD44 directly regulates YAP expres-
sion via active RhoA. Thereby, the HIPPO pathway becomes
blocked, which results in increased apoptosis resistance (306,
307). In a feedback loop, activated YAP binds to the promoter
of RHAMM, thereby inducing RHAMM transcription (308, 309)
(Figure 4B).
Besides via CD44-associating molecules, the direct interac-
tion between CD44 and HA strongly affects apoptosis resistance.
Exploring the effect of HA on the extent of DNA damage induced
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FIGURE 4 | CD44 interferes with apoptosis resistance in HSC/LIC.
(A) Four major pathways of RTK-promoted apoptosis protection are shown.
(i) CD44–HA binding is accompanied by activation of CD44-associated src,
ezrin phosphorylation, and PI3K activation, and assembly of a complex that
includes, in addition, HSP70 and the co-chaperone CDC37, which promotes
phosphorylation and activation of the ERBB2/ERBB3 RTK. (ii) The
CD44–ERBB2/ERBB3 complex also provides a strong stimulus for Cox-2
transcription, which interferes with caspase3 activation. (iii) CD44v6 binds HGF
and presents it to MET. Activation of the latter and the downstream signaling
cascades require concomitant activation of CD44 associated pERM and src.
Importantly, joining of signaling via the Ras/MAPK and the PI3K/Akt pathway
that rely on the CD44 cytoplasmic tail can be initiated without any additional
stimuli by a CD44v6-assembled matrix. (iv) CD44v3 binds proHBEGF, which
becomes cleaved via CD44-associated MMP7. HBEGF binds and activates
ERBB4. All of these CD44–RTK associations strongly promote activation of
signaling cascades that block apoptosis and upregulate anti-apoptotic proteins.
(B) Oxidative stress promotes merlin phosphorylation and dissociation from
CD44. Merlin plays an important role in controlling the Hippo pathway. In CD44v
expressing LIC, merlin is replaced by pERM, such that cIAP becomes increased
and caspase3 activation does not take place, forcing LIC resistance toward
cytotoxic drugs. (C) Particularly in HSC residing in the osteogenic niche, it has
been observed that CD44-attached highMW HA can become internalized
together with CD44, where HA acts as a catcher of ROI, which protects DNA
from damage. (D) MDR proteins are associated with activated CD44 (highMW
HA-ligated and associated with pERM). Instead, lowMW HA promotes CD44
and concomitantly MDR internalization, which is accompanied by a significant
increase in cytotoxic drug sensitivity. Maintenance of the complex between
CD44, pERM, actin, and MDR-1, as well as the recovery of the S100A/AnnexinII
complex indicates internalization within caveolae and/or GEM. As far as LIC
compete with HSC for the osteogenic niche, they will profit from the highMW HA
matrix that via CD44 stabilizes MDR proteins within the cell membrane
contributing to drug resistance.
by exogenous and endogenous oxidants revealed that CD44 in SC
internalizes HA by endocytosis. One of the functions of the inter-
nalized HA is the protection of DNA from oxidants. The authors
propose entrapment of iron ions. Thereby the Fenton’s reaction,
which produces secondary oxidative species becomes inhibited.
Alternatively, though not mutually exclusive, HA directly scav-
enges primary and secondary ROI, which results in intracellu-
lar HA degradation (310). Palmitoylation and GEM recruitment
of CD44 is a precondition for HA internalization (311). Thus,
attenuating oxidant-induced damage can proceed through direct
scavenging of oxidant molecules by HA (312) (Figure 4C).
Drug resistance can also be promoted through CD44v3–HA
binding, which via the Oct4-Sox2-Nanog complex induces miR-
302 transcription (74). The CD44–HA induced nuclear transloca-
tion of Nanog also leads to miR-21 production and upregulation
of apoptosis inhibitors and MDR1 (77, 313).
Last, the interplay between CD44 and HA accounts for rapid
drug elimination via drug transporters (288), which creates a
major obstacle in leukemia and cancer therapy (314). Both CD44
and HA contribute to drug resistance. MDR genes are associated
with CD44 and CD44 regulates expression of drug transporters.
This likely is due to HA-activated CD44 binding to Gab1, which
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promotes PI3K activation. Activated PI3K stimulates HA pro-
duction as well as MDR transporter expression (315, 316). Alter-
natively, though not mutually exclusive, HA binding to CD44
up-regulates p300 expression and its acetyltransferase activity.
This, in turn, promotes acetylating β-catenin and NFκB-p65.
Activated β-catenin and NFAT act as cotranscription factors with
NFκB in MDR1 transcription (317). The direct involvement of
HA was demonstrated by replacing high MW by low MWHA. In
the presence of high MW, HA activated CD44 is predominantly
recovered in GEM and is associated with ERM and actin. MDR1
is associated with CD44 and the association stabilizes MDR1
expression. Instead, low MW HA does not stabilize the complex,
but rather supports internalization such that all components of
the complex including S100A and Annexin II are recovered in
the cytoplasm (318). Whether the internalized complex becomes
degraded or released as exosomes has not been explored. Inde-
pendent of the answer to this question, the reduction of MDR1
in the cell membrane is accompanied by increased drug sus-
ceptibility (319). Notably, the three hyaluronan synthases are
supposed to produce HA of different size. However, this as well
as the major transcription factors engaged in HAS1, -2, and -
3 transcription remain to be defined. Transcriptional regulation
of hyaluronidases also awaits unraveling (320, 321). Taking into
account that hyaluronidase as well as small HA oligosaccharides
can improve drug efficacy (318), and that HA-CD44 cross-linking
regulates expression of drug transporters (315, 316), filling this
gap becomes demanding to improve therapeutic targeting of HA
[review in Ref. (322, 323)] (Figure 4D).
The major importance of CD44 in apoptosis resistance relies
(i) on the association of activated (HA-crosslinked) CD44/CD44v
with RTK, which promote activation of anti-apoptotic signaling
cascades, (ii) on interferences of CD44v6 with FAS trimerization,
and (iii) the engagement of CD44 in regulating drug-resistance
gene expression. The impact of CD44 is efficiently reinforced by
high MW, but not low MW HA, where the latter may open a
therapeutic window.
Open Questions
This review highlights the importance of CD44 in the crosstalk
between HSC/LIC and the surrounding matrix. However, due to
space constraints, this review does not cover the role of CD44
in all aspects of hematopoiesis and leukemia induction; this can
be found within an excellent review which also focuses on signal
transduction and transcription (324). Furthermore, while CD44-
based therapeutic concepts have been highlighted in individual
sectionswithin this review, there is some excellent literature which
describes CD44 antibody and vaccination-based therapeutic con-
cepts that may be of further interest to the reader (325–332).
However, there are a number of key issues/questions that need
to be addressed before a major therapeutic breakthrough can be
achieved:
1. More information on the active contribution of the niche is
required as well as the contribution of the individual compo-
nents. This includes the possible transfer of information, com-
prising miRNA, via exosomes and accounts for HSC and LIC.
2. There is insufficient information on the modulation of the
osteogenic niche by LIC, to safely protect HSC, if LIC was to be
targeted, and to reconstruct a destroyed niche for unimpaired
hematopoiesis.
3. The generation of LIC is not well understood. Again, the
possibility has to be taken into account that LIC are instructed
by surrounding cells, preferably HSC or MSC, via exosomes.
Furthermore, there is a paucity of knowledge on the decision
for self-renewal versus differentiation, which to some degree
also accounts for HSC.
4. Much progress has been made in homing, migration, and
signal transduction, which couldwell become the first question
to be comprehensively answered.
In summary, the specific therapeutic targeting of LSC is still
very much a field in its infancy (323). However, there is justified
hope that this may change in the near future.
Conclusion
Stem cells require a niche, which has been particularly well
explored for HSC, where the central importance of the CD44–HA
interaction, including more recently the cellular stroma elements,
is amply demonstrated. The CD44–HA crosstalk promotes adhe-
sion and via cytokines/chemokines harbored in the BM-Str,
homing, and migration of HSC as well as HSC quiescence and
resistance to lowoxygen pressure. LIC sharewithHSC the require-
ment for the crosstalk with the stroma to promote adhesion, hom-
ing, and migration. Apoptosis resistance of LIC, though strikingly
dependent on the CD44-HA crosstalk, proceeds differently to that
of HSC predominantly via CD44v and the cooperation with RTK,
proteases, and drug transporters.
The abundant array of HA-bound CD44-initiated activities
relies on the cooperation of CD44 with multiple membrane
molecules including integrins, chemokine receptors, RTK, and
proteases as well as its transient association with cytoskele-
tal linker molecules and cytoplasmic signal transducers, which
includes central stem cell fate regulators. The multitude of inter-
actions is fostered by the GEM location of CD44, which also
promotes the proximity to proteases. Proteases facilitate CD44
cleavage, where the CD44-ICD acts as a cotranscription factor. It
has been suggested, but needs further approval, that CD44-ICD
also regulates miR transcription/repression of CD44 cooperation
partners, thereby creating an additional feedback loop.
In view of the most promising results in leukemia therapy by
blocking CD44, awareness increased on possible selective differ-
ences between HSC and LIC in the crosstalk with the osteogenic
niche. Several elegant and sophisticated studies clearly demon-
strated the existence of differences not only between HSC and
LIC but also between distinct leukemia. Progress in this field will
greatly facilitate selective therapeutic interference with LIC hom-
ing and may allow for corrections of the LIC-distorted osteogenic
niche. The latter as well as the interaction with the vascular niche
and homing into the osteogenic niche is of particular interest in
view of theHSC transfer being frequently a last chance for curative
therapy. Further clarifying HA production and degradation may
also open new avenues for a therapeutic dissection between the
HSC- and the LIC–HA crosstalk. Last, not least, uncovering the
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importance of miRNA and the role of exosomes in miRNA trans-
fer will add optimizing the HSC–HA crosstalk in the osteogenic
niche and will allow interfering with niche destructing activities
of LIC.
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